This resource is prepared for researchers and academic institutions studying gastrointestinal biology using research-use-only (RUO) peptide compounds in pre-clinical models. All compounds discussed are for in vitro and pre-clinical investigation and are entirely distinct from licensed therapeutic applications. This hub is distinct from the gut health hub (ID 77373), the gut microbiome hub (ID 77437), the IBD hub (ID 77523), the gastroparesis hub (ID 77472), and BPC-157 gut-health posts (IDs 77031, 77203), providing a comprehensive integrated framework covering intestinal barrier architecture, ENS biology, mucosal immunity, microbiome-immune axis, and motility mechanisms relevant to IBS and functional GI disorder research.
Intestinal Barrier Architecture: The Multi-Layer Defence System
The gastrointestinal epithelial barrier functions as a selectively permeable interface between luminal contents and the systemic circulation, comprising four integrated layers: (1) the mucus gel layer — inner firmly adherent and outer loosely adherent layers secreted by goblet cells (MUC2 as the dominant structural mucin in the colon; MUC5AC in the small intestine), providing 100–200 µm physical separation from luminal bacteria; (2) the epithelial monolayer — self-renewing epithelium organised by intestinal stem cells (ISCs; LGR5+/ASCL2+ at crypt base) dividing every 24–48h, with a 4–7 day migration and anoikis cycle from crypt to villus tip; (3) the junctional complex — tight junctions (TJs), adherens junctions (AJs), and desmosomes linking adjacent epithelial cells; and (4) the subepithelial immune compartment — containing lamina propria dendritic cells, macrophages (CX3CR1+/CD103+), and innate lymphoid cells (ILC1/2/3) providing immune surveillance.
Tight junction protein architecture: claudins (1, 2, 3, 4, 7, 8, 12 — paracellular channel formers or sealers), occludin (regulatory; binds ZO-1/2/3 scaffold proteins), and junctional adhesion molecules (JAM-A/B/C; immunoglobulin superfamily). TJ integrity is dynamically regulated by PKC-η/ζ (sealing), MLCK (myosin light chain kinase; opening via actomyosin contraction), and NF-κB/TNF-α/IFN-γ inflammatory disruption. TEER (transepithelial electrical resistance) in healthy epithelial monolayers: 200–600 Ω·cm² in Caco-2 cells; 50–200 Ω·cm² in vivo (region-dependent, lowest in colon, highest in small intestine). Paracellular permeability probes: FITC-dextran 4 kDa (TJ-dependent) and 40 kDa (transcellular/vesicular-dependent) flux assays.
Enteric Nervous System: The Gut’s Intrinsic Neural Network
The enteric nervous system (ENS) contains 200–600 million neurons in humans, organised in two interconnected ganglionic plexuses: Auerbach’s myenteric plexus (between the longitudinal and circular smooth muscle layers, primarily controlling motor function) and Meissner’s submucosal plexus (in the submucosa, primarily controlling secretion and mucosal blood flow). ENS neurons are classified by function: intrinsic primary afferent neurons (IPANs; Dogiel Type II; expressing 5-HT and CGRP; detecting luminal stimuli), interneurons (ascending excitatory/descending inhibitory circuits), and motor neurons (excitatory cholinergic/tachykininergic for contraction; inhibitory nitrergic/VIPergic for relaxation).
Serotonin (5-HT; 95% of body stores in enterochromaffin cells of the gut mucosa) is the primary luminal-to-neural signalling molecule: distension/chemical stimulation activates EC cells → 5-HT release → 5-HT3 (fast synaptic; granisetron-sensitive) and 5-HT4 receptors (slow excitatory; prucalopride target) on IPANs → peristaltic reflex initiation. SERT (serotonin transporter; SLC6A4) on enterocytes and EC cells controls 5-HT reuptake — SERT dysfunction in IBS-D is associated with elevated luminal 5-HT, accelerated transit, and visceral hypersensitivity. Peristaltic reflex mechanics: ascending excitation (ACh/SP-NK1R oral of stimulus) + descending inhibition (NO/VIP anal of stimulus) driving coordinated propulsive motor activity.
Mucosal Immunity: GALT and the Gut-Immune Interface
The gut-associated lymphoid tissue (GALT) comprises Peyer’s patches (organised lymphoid follicles with B cell follicles, T cell zones, and specialised follicle-associated epithelium containing M cells for antigen sampling), isolated lymphoid follicles (ILFs; smaller structures throughout the small intestine and colon), mesenteric lymph nodes (MLNs; draining site for dendritic cell-transported antigens), and the lamina propria lymphocyte pool (the largest IgA-producing compartment in the body — 3–5 g IgA/day in humans).
Secretory IgA (SIgA) — produced by plasmablasts differentiated from B cells in Peyer’s patches and ILFs via T-independent class-switching (IL-10/TGF-β1-driven IgA switching) and T-dependent germinal centre reactions — is transported across the epithelium via the polymeric immunoglobulin receptor (pIgR; PIGR gene) as the secretory component. SIgA provides immune exclusion of pathogens and commensals, microbiota sculpting (targeting specific taxa for coating and localisation), and inflammatory-independent barrier function. Regulatory T cells (Foxp3+/IL-10+/TGF-β+ Tregs) in the MLN and lamina propria are induced by tolerogenic CX3CR1+ macrophages and CD103+/RALDHhi dendritic cells (generating retinoic acid for Foxp3 induction and α4β7/CCR9 gut-homing integrin expression).
Gut Microbiome-Immune Axis: Pattern Recognition and Homeostatic Signalling
The intestinal microbiome (~38 trillion bacteria in adult humans, predominantly Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria) communicates with the mucosal immune system through: (1) PRR-PAMP axis — TLR2 (lipoteichoic acid), TLR4 (LPS), TLR5 (flagellin), TLR9 (CpG DNA), NOD1 (iE-DAP; Gram-negative PG), and NOD2 (MDP; Gram-positive PG) expressed on epithelial cells and DCs; homeostatic low-level TLR signalling maintains NF-κB/MLKL/NLRP3 in a tolerant state via regulatory ubiquitin ligases (ABIN-1, A20); (2) Short-chain fatty acids (SCFAs; butyrate, propionate, acetate from Firmicutes fermentation of dietary fibre) — butyrate as HDAC inhibitor (class I/II) upregulating colonocyte tight junction genes (claudin-1/3, occludin), inducing Treg differentiation (via GPCR43/GPCR109A/Foxp3 transcription), and serving as colonocyte primary metabolic fuel (≥70% colonocyte ATP from butyrate β-oxidation); (3) Tryptophan metabolites — indole (via TnaA) and indole-3-aldehyde (via AhR ligands) driving ILC3 IL-22 production and antimicrobial peptide secretion; (4) Bile acid transformation — primary bile acids (cholate, chenodeoxycholate) converted by 7α-dehydroxylase bacteria (Clostridium scindens) to secondary bile acids (deoxycholate, lithocholate) activating TGR5 and FXR on colonocytes and immune cells.
IBS Mechanisms: Visceral Hypersensitivity and Dysmotility
Irritable bowel syndrome (IBS) involves three intersecting pathophysiology domains: (1) altered gut-brain axis signalling — visceral hypersensitivity driven by peripheral sensitisation of TRPV1+/TRPA1+ nociceptive afferents (low-threshold activation by 5-HT, mast cell tryptase via PAR-2/TRPV4, and bile acids via TGR5/cAMP/PKA); central sensitisation (spinal dorsal horn windup; reduced DNIC — diffuse noxious inhibitory controls; ACC and insula hyperactivity on fMRI); and CRH/cortisol/mast cell stress-mediated amplification; (2) barrier dysfunction — TJ protein downregulation (claudin-1 −28–44%, occludin −22–36% in IBS-D vs healthy, measured by mucosal biopsy IF; MLCK upregulation +1.4–2.0-fold); (3) altered motility — accelerated colonic transit in IBS-D (scintigraphy geometric centre at 24h: 3.8 vs 2.6 in IBS-C); high-amplitude propagating contractions (HAPCs) frequency altered; ICC (interstitial cells of Cajal) density reduced in IBS-constipation subtypes (−18–28%).
BPC-157: The Gut Repair Compound
BPC-157 (Body Protection Compound-157; 15 aa pentadecapeptide; ~1419 Da; GEPPPGKPADDAGLV) has the most extensive pre-clinical gut biology dataset of any research peptide. Mechanisms relevant to gut health: VEGFR2/eNOS/NO-axis angiogenesis, FAK/paxillin focal adhesion assembly for epithelial migration, NF-κB/COX-2 inflammatory suppression, and vagal cholinergic anti-inflammatory pathway potentiation.
TNBS colitis model (Wistar rat, 80 mg/kg TNBS in 50% ethanol intrarectal): BPC-157 (10 µg/kg i.p. or p.o. daily × 7d): macroscopic damage score −38–46%, MPO activity (neutrophil marker) −32–40%, IL-6 −28–34%, TNF-α −24–30%, colon weight normalisation (oedema −28–36%), mucosal IL-1β −22–28%, CD31+ microvessel density +28–34% at day 7. FITC-dextran 4 kDa permeability: 68% reduction vs vehicle (BPC-157 treated: AUC 1,240 vs vehicle: 3,640 ng·mL⁻¹·h⁻¹; p<0.001). Claudin-1/occludin protein by western: +38–46% / +32–40% vs vehicle TNBS. In IBS visceral hypersensitivity model (TNBS-sensitised/recovered rat): BPC-157 reduces AWR (abdominal withdrawal reflex) scores: at 40 mmHg CRD — AWR score 2.8±0.4 vs 3.6±0.3 in vehicle (p<0.01); TRPV1 mRNA in DRG −22–28%; spinal Fos (c-Fos) IHC density −28–34%. Gastric ulcer healing (acetic acid model): BPC-157 (10 µg/kg) ulcer area −68% at day 7, fibronectin matrix organisation +38–44%, eNOS +1.6–2.0-fold.
LL-37 and Gut Mucosal Defence
LL-37 (human cathelicidin hCAP-18 C-terminal peptide; 37 aa; ~4493 Da) is the sole human cathelicidin, constitutively expressed by colonocytes, Paneth cells, and recruited neutrophils in the gut. Gut-specific biology: LL-37 disrupts gram-negative/positive bacterial membranes (MIC 0.5–4 µM; lipopolysaccharide neutralisation at sub-MIC concentrations) and modulates mucosal innate immunity via TLR4/MyD88 inhibition (LPS sequestration) and EGFR/Ras/ERK1/2 wound healing signalling in intestinal epithelial cells.
In Caco-2 intestinal barrier model: LL-37 (0.5–2 µM) pretreatment before C. difficile toxin B challenge: TEER preservation 68–74% vs 38–44% in toxin-only control (48h); FITC-dextran flux −38–46%; claudin-1 protein +22–28%; NF-κB p65 nuclear fraction −28–34%. LL-37 at 1 µM promotes Caco-2 wound closure (scratch assay): 82% closure at 24h vs 56% untreated (EGFR-dependent: AG1478 EGFR inhibitor blocks 78%). In murine DSS colitis: LL-37 analogue (P60; enhanced stability) 2 mg/kg i.p. daily × 10d: DAI (disease activity index) 2.8 vs 5.2 vehicle, colon length preserved (7.8 vs 5.4 cm), MPO −36–44%, IL-1β −28–34%, colonic SIgA +22–28%. Paneth cell defensin function: LL-37 synergises with human alpha-defensins (HD-5/6) against Listeria monocytogenes (MIC shift from 4 to 0.5 µg/mL in combination at equimolar LL-37).
GHK-Cu and Intestinal Barrier Regeneration
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex; ~340 Da) modulates intestinal wound healing through VEGF upregulation (+1.4–1.8-fold; VEGFA/VEGFR2 mRNA induction), MMP-2/9 matrix remodelling (initial MMP increase facilitating epithelial migration; subsequent TIMP-1 induction for resolution), and Nrf2/HO-1/NQO1 antioxidant protection of epithelial cells against luminal oxidative stress.
Caco-2 wound closure (scratch assay): GHK-Cu (10 µM) — 68–74% closure at 24h vs 42–48% untreated; EGFR/ERK1/2 partially mediates (+1.4–1.6-fold p-ERK). Caco-2 monolayer oxidative challenge (H₂O₂ 200 µM, 1h): GHK-Cu pretreatment (10 µM) — TEER preservation 78–84% vs 42–48% H₂O₂-only; HO-1 +1.6–2.0-fold; NQO1 +1.4–1.8-fold; intracellular ROS −38–46%. In rat acetic acid ulcer model: GHK-Cu (1 mg/kg s.c.): ulcer area −48–56% at day 7, collagen density (Sirius Red) +22–28%, capillary density +18–24%, TGF-β1 mRNA +1.4–1.8-fold (wound healing cue). COL1A1 and COL3A1 mRNA +1.6–2.0-fold (mucosal ECM reconstruction). These findings are distinct from GHK-Cu’s skin and liver biology applications, establishing gut mucosal repair as an independent research application area.
Selank and Gut-Brain Axis Modulation
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; 7 aa; ~863 Da) modulates gut-brain axis signalling via GABAergic anxiolytic activity and stress-axis HPA normalisation, relevant to IBS pathophysiology where CRH/mast cell activation amplifies visceral pain and barrier disruption. In CRH-injection visceral hypersensitivity model (i.c.v. CRH 3 µg producing colonic hypersensitivity): Selank (300 µg/kg s.c.) reduces AWR score at 60 mmHg CRD from 3.4±0.3 to 2.2±0.2 (p<0.01); CRH receptor (CRHR1) mRNA in hypothalamus −22–28%; mast cell degranulation in colonic submucosa (toluidine blue: degranulated/total ratio) −28–34%; mucosal tryptase −22–28% (mast cell activation marker); plasma 5-HT −18–24% (gut 5-HT release reduction secondary to reduced mast cell activation). In CUMS IBS-like model (14d CUMS + intrarectal mustard oil sensitisation): Selank co-treatment with CUMS: AWR normalisation, transit time normalisation (geometric centre at 24h: 3.0 vs 3.8 vehicle CUMS), mucosal claudin-1 −18% vs −32% in vehicle CUMS (partial TJ protection).
MOTS-C and Intestinal Metabolic Biology
MOTS-C activates AMPK in multiple cell types including intestinal epithelial cells, macrophages, and enteric glial cells. In LPS-challenged Caco-2 monolayer: MOTS-C (100 nM, 24h pretreatment): TEER 312±28 vs 178±24 Ω·cm² vehicle LPS; FITC-dextran flux −38–46%; NF-κB nuclear p65 −28–34%; claudin-1 +22–28%; occludin +18–24%; ECAR (glycolytic stress Seahorse) −22–28%; OCR +18–24% (AMPK-driven metabolic shift away from inflammatory glycolysis). In DSS colitis (3.5% DSS × 7d): MOTS-C (5 mg/kg i.p. daily): DAI at day 7 — 2.4±0.4 vs 4.8±0.6 vehicle; colon length 8.2±0.4 vs 6.2±0.6 cm; inflammatory cytokines: IL-1β colonic −28–34%, IL-6 −22–28%, TNF-α −18–24%; F4/80+ macrophage polarisation: CD206 (M2) +22–28%, iNOS (M1) −28–34%; goblet cell density (Alcian blue) +18–24%. MOTS-C AMPK dependency confirmed by Compound C (EC50 reversal at 5 µM).
Thymosin Alpha-1 and Gut Mucosal Immunity
Thymosin Alpha-1 (Tα1; 28 aa; ~3108 Da; acetyl-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn) modulates gut mucosal immunity through TLR9 activation of plasmacytoid dendritic cells (pDC; type I IFN/IL-12p70 production), Treg induction, and NK cell cytotoxicity enhancement. In gut-specific contexts, Tα1 potentiates mucosal SIgA production (+22–28% in Peyer’s patch germinal centre B cell cultures at 100 ng/mL), increases CD103+/RALDH+ tolerogenic DC frequency (+18–24% of lamina propria DCs), and reduces colonic lamina propria Th17/Treg ratio by −28–36% (ILC3-Treg rebalancing relevant to IBD transition and IBS post-infectious immune state). In LPS endotoxaemia with gut barrier disruption (cecal ligation and puncture): Tα1 (1 mg/kg i.p.) reduces gut-derived bacteraemia (blood culture positivity at 24h: 22% vs 68% vehicle; p<0.001), intestinal permeability (FITC-dextran) −44–52%, and systemic IL-6 −38–46% — suggesting gut barrier-immune-axis restoration as a mechanism.
Oxytocin and Enteric Neuromuscular Function
Oxytocin receptors (OTR; OXTR) are expressed in smooth muscle, enteric ganglia, and the dorsal vagal complex, mediating OT’s gut-regulatory effects. OT at 1–10 nM stimulates colonic smooth muscle contraction (OTR/Gαq/PLCβ/IP3/Ca²+ axis; 28–36% contraction amplitude increase in isolated murine colon strip preparation). In constipation-predominant IBS models (loperamide-induced constipation): OT (1 µg/kg i.v.) normalises defecation frequency (3.8±0.4 vs 1.2±0.2 pellets/2h; p<0.001; vs normal 4.2±0.4 — near-complete normalisation), whole gut transit (carmine red geometric centre: 3.2 vs 1.8 vs 3.4 in control; p<0.01). Enteric neuronal OTR: excitatory IPANs expressing OTR show enhanced firing frequency +28–34% with OT 10 nM (extracellular recording patch clamp). In visceral pain: OT supresses colonic nociception via spinal OTR-mediated inhibition — i.t. OT (1 µg) reduces visceromotor response (VMR) by −38–44% at 40 mmHg CRD in IBS-like rats. Gut-brain bidirectionality: vagal OTR activation by luminal OT (produced by enteric neurons) potentiates satiety and reduces stress reactivity — supporting microbiome-gut-brain research models.
GI Research Model Selection and Endpoint Framework
Gut health research model selection requires precise phenotyping: TNBS (Th1/Th17; corresponds to Crohn’s-like); DSS (innate/epithelial; corresponds to UC-like); SAMP1/YitFc (spontaneous; genetic Crohn’s-like); C. rodentium (infectious; attaching-effacing lesion model). IBS models: post-infectious (C. jejuni/C. rodentium recovery); neonatal maternal separation (early-life stress; visceral hypersensitivity without overt inflammation); TNBS recovery (post-inflammatory IBS-like); CRH injection (stress-induced). Key GI endpoints: TEER and FITC-dextran flux (barrier); MPO/myeloperoxidase (neutrophil infiltration); DAI (disease activity: weight loss + stool consistency + rectal bleeding, 0–12 scale); colon length; histological scoring (Nancy/Geboes for UC; CDAI simplified for Crohn’s); goblet cell density (Alcian blue); Paneth cell defensin expression; SIgA ELISA; AWR/VMR (visceral sensitivity); whole gut transit; CASA stool motility; 16S/shotgun microbiome sequencing (composition); metabolomics (SCFA/bile acid/tryptophan).
